0
Pulmonary Procedures |

EBUS-TBNA and Melanoma FREE TO VIEW

Amir Khan; Carolina Carillo; William Geddie; Kazuhiro Yasufuku, MD
Author and Funding Information

Department of Pathology - University of Toronto, Toronto, ON, Canada


Chest. 2014;146(4_MeetingAbstracts):736A. doi:10.1378/chest.1991916
Text Size: A A A
Published online

Abstract

SESSION TITLE: EBUS and Advanced Bronchoscopy Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM

PURPOSE: Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) is currently the diagnostic modality of choice for mediastinal adenopathy and lung cancer staging. Melanoma primary or metastatic to lungs is rare and presents diagnostic and therapeutic challenges. The clinical utility of EBUS-TBNA for evaluation of metastatic melanoma to lungs is not well defined. The aim of our study is to assess if EBUS-TBNA sampling is adequate for morphological diagnosis and molecular DNA analysis of melanoma at our institution.

METHODS: A retrospective review of all patients who underwent EBUS-TBNA in the last five years and suspicious of recurrence of melanoma to the lung was performed. EBUS-TBNA procedure was performed as OPD under conscious sedation. The followings were collected: Age & gender, clinical history and presentation, primary site of origin, total no. of lymph nodes/mass biopsied, presence or absence of ROSE, final diagnosis and molecular analysis (including BRAF), clinical follow up.

RESULTS: Of the 1358 consecutive patients reviewed, we identified 7 patients who had EBUS-TBNA and had a diagnosis of melanoma; all were enrolled in this study. There were 5 men and 2 women with an average age of 60.3 years (± SD 11.4). 4/7 had metastatic melanoma, 1/7 had NSCLC and 2/7 had sarcoidosis. The primary site of origin of 4 metastatic melanoma lesions were foot, shoulder, back & scalp. One patient recurred after 18.5 years of the initial diagnosis and the average primary diagnosis time in the remaining 3 lesion was 9 years. Average biopsied lymph nodes station were two. ROSE was present in 2/4 cases; in all 4 patients IHC analysis performed was positive for S100, HMB45 & Melan A. One patient had BRAF mutation at time of his primary diagnosis, in the remaining 3 patients all had sufficient sample for BRAF gene mutations analysis (2/3 +ive). No serious post-procedural complications with EBUS were recorded. 4/4 patients are alive to date (mean follow-up 1 year).

CONCLUSIONS: We conclude that EBUS-TBNA can be performed satisfactorily for morphologic and immunohistochemical verification of the diagnosis as well as sufficient DNA analysis for BRAF testing.

CLINICAL IMPLICATIONS: Ebus can adequately sample for morphologic and immunohistochemical verification of the diagnosis as well as DNA testing in metatstatic melanoma.

DISCLOSURE: The following authors have nothing to disclose: Amir Khan, Carolina Carillo, William Geddie, Kazuhiro Yasufuku

No Product/Research Disclosure Information


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543